Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC labeling reg extension

This article was originally published in The Tan Sheet

Executive Summary

FDA expects to respond to industry requests for a two-year extension of the OTC labeling final rule implementation date by Jan. 28, the agency states in recent letters to CHPA and CTFA. In the letters, FDA asks the trade groups to let it complete the request and refrain from soliciting further meetings on the subject. The agency met with CHPA and CTFA Jan. 4 and Jan. 11. "Because the primary implementation date for the rule is still more than 16 months away," FDA says, "we believe a two-week period to allow for completion of our response is reasonable." The trade associations requested the extension in October (1"The Tan Sheet" Oct. 11, 1999, p. 6)

You may also be interested in...



CHPA Requests Two-Year Extension For OTC Labeling Final Rule

A two-year extension of the implementation deadlines for FDA's final rule on over-the-counter drug labeling is requested by the Consumer Healthcare Products Association in a citizen petition submitted to the agency Oct. 1.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS090791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel